BIOGEN INC. is 3.9x more valuable than ImmunityBio, Inc. by market capitalization ($28.68 B vs $7.31 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IBRX | BIIB |
|---|---|---|
| Market cap | $7.31 B | $28.68 B |
| US-listed rank | #1120 | #476 |
| Revenue (latest FY) | $113.29M | $9.89B |
| Net income (latest FY) | -$351.50M | $1.29B |
| Net margin | -310.3% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 528 | 2,690 |
BIOGEN INC. is 3.9x more valuable than ImmunityBio, Inc. by market capitalization ($28.68 B vs $7.31 B).
In their latest fiscal years, ImmunityBio, Inc. reported $113.29M in revenue while BIOGEN INC. reported $9.89B.
Full pages: ImmunityBio, Inc. and BIOGEN INC., or browse the full rankings.